Literature DB >> 23591130

Evaluation of longevity enhancing compounds against transactive response DNA-binding protein-43 neuronal toxicity.

Arnaud Tauffenberger1, Carl Julien, J Alex Parker.   

Abstract

In simple systems, lifespan can be extended by various methods including dietary restriction, mutations in the insulin/insulin-like growth factor (IGF) pathway or mitochondria among other processes. It is widely held that the mechanisms that extend lifespan may be adapted for diminishing age-associated pathologies. We tested whether a number of compounds reported to extend lifespan in C. elegans could reduce age-dependent toxicity caused by mutant TAR DNA-binding protein-43 in C. elegans motor neurons. Only half of the compounds tested show protective properties against neurodegeneration, suggesting that extended lifespan is not a strong predictor for neuroprotective properties. We report here that resveratrol, rolipram, reserpine, trolox, propyl gallate, and ethosuximide protect against mutant TAR DNA-binding protein-43 neuronal toxicity. Finally, of all the compounds tested, only resveratrol required daf-16 and sir-2.1 for protection, and ethosuximide showed dependence on daf-16 for its activity. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23591130     DOI: 10.1016/j.neurobiolaging.2013.03.014

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  11 in total

1.  Ethosuximide Induces Hippocampal Neurogenesis and Reverses Cognitive Deficits in an Amyloid-β Toxin-induced Alzheimer Rat Model via the Phosphatidylinositol 3-Kinase (PI3K)/Akt/Wnt/β-Catenin Pathway.

Authors:  Shashi Kant Tiwari; Brashket Seth; Swati Agarwal; Anuradha Yadav; Madhumita Karmakar; Shailendra Kumar Gupta; Vinay Choubey; Abhay Sharma; Rajnish Kumar Chaturvedi
Journal:  J Biol Chem       Date:  2015-09-29       Impact factor: 5.157

2.  Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons.

Authors:  Julie Vérièpe; Lucresse Fossouo; J Alex Parker
Journal:  Nat Commun       Date:  2015-06-10       Impact factor: 14.919

Review 3.  Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions.

Authors:  Chenyin Wang; Chaogu Zheng
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

4.  Conserved pharmacological rescue of hereditary spastic paraplegia-related phenotypes across model organisms.

Authors:  Carl Julien; Alexandra Lissouba; Surya Madabattula; Yasmin Fardghassemi; Cory Rosenfelt; Alaura Androschuk; Joel Strautman; Clement Wong; Andrew Bysice; Julia O'sullivan; Guy A Rouleau; Pierre Drapeau; J Alex Parker; François V Bolduc
Journal:  Hum Mol Genet       Date:  2016-01-06       Impact factor: 6.150

5.  Heritable transmission of stress resistance by high dietary glucose in Caenorhabditis elegans.

Authors:  Arnaud Tauffenberger; J Alex Parker
Journal:  PLoS Genet       Date:  2014-05-01       Impact factor: 5.917

Review 6.  Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis elegans.

Authors:  Martine Therrien; J Alex Parker
Journal:  Front Genet       Date:  2014-04-17       Impact factor: 4.599

7.  Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression.

Authors:  Xi Chen; Hannah V McCue; Shi Quan Wong; Sudhanva S Kashyap; Brian C Kraemer; Jeff W Barclay; Robert D Burgoyne; Alan Morgan
Journal:  Mol Neurodegener       Date:  2015-09-29       Impact factor: 14.195

8.  Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol.

Authors:  Sudhanva S Kashyap; James R Johnson; Hannah V McCue; Xi Chen; Matthew J Edmonds; Mimieveshiofuo Ayala; Margaret E Graham; Robert C Jenn; Jeff W Barclay; Robert D Burgoyne; Alan Morgan
Journal:  Hum Mol Genet       Date:  2014-06-19       Impact factor: 6.150

Review 9.  Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases.

Authors:  Xi Chen; Jeff W Barclay; Robert D Burgoyne; Alan Morgan
Journal:  Chem Cent J       Date:  2015-11-26       Impact factor: 4.215

10.  A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action.

Authors:  Shi Quan Wong; Alistair Jones; Steven Dodd; Douglas Grimes; Jeff W Barclay; Anthony G Marson; Vincent T Cunliffe; Robert D Burgoyne; Graeme J Sills; Alan Morgan
Journal:  J Neurosci Methods       Date:  2018-09-03       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.